Fludarabine Phosphate
FDA-approved product (injectable, injection), marketed as Fludara, Fludarabine Phosphate, Oforta.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 1 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Cancer
- Chronic lymphocytic leukemia
- Neoplasm
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Purine analogues
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli. It was surfaced computationally for further investigation; it is not an established treatment for this infection.
AI-predicted activity
AI prediction · nothing measured- MRSA36.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- E. coli44.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae23.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis35.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Fludarabine Phosphate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- FurazolidoneExisting use: Other antiinfectives and antiseptics91.4% AI-predicted activityagainst M. tuberculosisLab records exist49 registered studies
- TriflupromazineExisting use: Psychosis90.6% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- ValdecoxibExisting use: Dysmenorrhea, Osteoarthritis, Rheumatic disease and 1 more88.6% AI-predicted activityagainst M. tuberculosisLab records exist31 registered studies
- CelecoxibExisting use: Ankylosing spondylitis, Cancer, Colorectal neoplasm and 15 more87.6% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- Dorzolamide HydrochlorideExisting use: Glaucoma, Ocular hypertension, Open-angle glaucoma86.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- MethazolamideExisting use: Glaucoma, Open-angle glaucoma85.6% AI-predicted activityagainst M. tuberculosisLab records exist11 registered studies
- AcetazolamideExisting use: Altitude sickness, Angle-closure glaucoma, Congestive heart failure and 5 more85.2% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- Trifluoperazine HydrochlorideExisting use: Anxiety disorder, Mental or behavioural disorder, Psychosis and 1 more84.6% AI-predicted activityagainst M. tuberculosis1 registered study
- TriclosanExisting use: Phenol and derivatives, Medicated dressings with antiinfectives84.2% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- NitrofurazoneExisting use: Eye infection, Leishmaniasis, Trypanosomiasis84.0% AI-predicted activityagainst M. tuberculosis8 registered studies
- BrinzolamideExisting use: Glaucoma, Ocular hypertension, Open-angle glaucoma83.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- ZonisamideExisting use: Epilepsy, Focal-onset seizure, Partial epilepsy and 1 more82.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
A Study to Investigate the Efficacy and Safety of OTL-203 in Subjects With MPS-IH Compared With Standard of Care With Allogeneic HSCT
NCT06149403 · start 2023-12-11
Registered record
- Registry ID
- NCT06149403
- Conditions
- MPS-IH (Hurler Syndrome)
- Interventions
- Experimental: OTL-203; Active Comparator: Allo-HSCT
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Active not recruiting
- Start
- 2023-12-11
- Completion
- 2031-03
- Enrolment
- 41
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMPS-IH (Hurler Syndrome)InterventionExperimental: OTL-203; Active Comparator: Allo-HSCTPhasePhase 3Registry statusActive not recruitingJY231 Injection in the Treatment of Relapsed or Refractory B-cell Lymphoma
NCT06045585 · start 2023-08-18
Registered record
- Registry ID
- NCT06045585
- Conditions
- Relapsed or Refractory B-cell Lymphoma
- Interventions
- infusion of JY231 injection
- Study type
- INTERVENTIONAL
- Phase
- Early phase 1
- Registry status
- Unknown
- Start
- 2023-08-18
- Completion
- 2025-12-31
- Enrolment
- 20
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionRelapsed or Refractory B-cell LymphomaInterventioninfusion of JY231 injectionPhaseEarly phase 1Registry statusUnknownCytokine-induced Memory-like NK Cells in Combination With Chemotherapy in Pediatric Patents With Refractory or Relapsed AML
NCT04354025 · start 2023-06-30
Registered record
- Registry ID
- NCT04354025
- Conditions
- Refractory Acute Myeloid Leukemia; Relapsed Acute Myeloid Leukemia
- Interventions
- Cytokine induced memory-like NK cells; Fludarabine; Ara-C; G-CSF; Interleukin-2; Leukapheresis
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Withdrawn
- Start
- 2023-06-30
- Completion
- 2028-07-31
- Enrolment
- 0
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionRefractory Acute Myeloid Leukemia; Relapsed Acute Myeloid LeukemiaInterventionCytokine induced memory-like NK cells; Fludarabine; Ara-C; G-CSF +2 morePhasePhase 2Registry statusWithdrawnE7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
NCT05686226 · start 2023-03-07
Registered record
- Registry ID
- NCT05686226
- Conditions
- Cervical Cancer; Throat Cancer; Oropharynx Cancer; Anal Cancer; Vulva Cancer; Vaginal Cancer; Penile Cancer; Metastatic Cancer; HPV-Related Malignancy; HPV-Related Carcinoma; HPV-Related Cervical Carcinoma; HPV-Related Squamous Cell Carcinoma; HPV-Related Adenocarcinoma; HPV Positive Oropharyngeal Squamous Cell Carcinoma; HPV-Associated Vaginal Adenocarcinoma; HPV-Related Adenosquamous Carcinoma; HPV-Related Endocervical Adenocarcinoma; HPV-Related Anal Squamous Cell Carcinoma; HPV-Related Penile Squamous Cell Carcinoma; HPV-Related Vulvar Squamous Cell Carcinoma; HPV Positive Rectal Squamous Cell Carcinoma
- Interventions
- E7 TCR-T cells; Aldesleukin
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Recruiting
- Start
- 2023-03-07
- Completion
- 2027-01-01
- Enrolment
- 20
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCervical Cancer; Throat Cancer; Oropharynx Cancer; Anal Cancer +17 moreInterventionE7 TCR-T cells; AldesleukinPhasePhase 2Registry statusRecruitingChidamide Bridging for CAR-T Therapy
NCT05370547 · start 2022-05-25
Registered record
- Registry ID
- NCT05370547
- Conditions
- Non Hodgkin's Lymphoma
- Interventions
- Chidamide; Fludarabine and cyclophosphamide; Anti-CD19 CAR-T cells
- Study type
- INTERVENTIONAL
- Phase
- Phase 1 / Phase 2
- Registry status
- Unknown
- Start
- 2022-05-25
- Completion
- 2025-06-30
- Enrolment
- 120
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionNon Hodgkin's LymphomaInterventionChidamide; Fludarabine and cyclophosphamide; Anti-CD19 CAR-T cellsPhasePhase 1 / Phase 2Registry statusUnknownTesting a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults With Relapsed/Refractory Osteosarcoma and Neuroblastoma, GD2-CAR PERSIST Trial
NCT04539366 · start 2022-01-25
Registered record
- Registry ID
- NCT04539366
- Conditions
- Recurrent Childhood Neuroblastoma; Recurrent Childhood Osteosarcoma; Recurrent Neuroblastoma; Recurrent Osteosarcoma; Refractory Childhood Neuroblastoma; Refractory Childhood Osteosarcoma; Refractory Neuroblastoma; Refractory Osteosarcoma
- Interventions
- Biopsy Procedure; Biospecimen Collection; Bone Marrow Aspiration; Bone Marrow Biopsy; Cyclophosphamide; Echocardiography Test; Fludarabine Phosphate; GD2-CAR-expressing Autologous T-lymphocytes; Imaging Procedure; Magnetic Resonance Imaging of the Heart; Multigated Acquisition Scan; Questionnaire Administration
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Suspended
- Start
- 2022-01-25
- Completion
- 2040-12-31
- Enrolment
- 73
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionRecurrent Childhood Neuroblastoma; Recurrent Childhood Osteosarcoma; Recurrent Neuroblastoma; Recurrent Osteosarcoma +4 moreInterventionBiopsy Procedure; Biospecimen Collection; Bone Marrow Aspiration; Bone Marrow Biopsy +8 morePhasePhase 1Registry statusSuspendedCD19-CAR_Lenti T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ ALL and DLBCL or PML
NCT04787263 · start 2021-03-04
Registered record
- Registry ID
- NCT04787263
- Conditions
- Acute Lymphoblastic Leukemia; Diffuse Large B Cell Lymphoma; Primary Mediastinal Lymphoma
- Interventions
- CD19-CAR_Lenti T cell
- Study type
- INTERVENTIONAL
- Phase
- Phase 1 / Phase 2
- Registry status
- Active not recruiting
- Start
- 2021-03-04
- Completion
- 2038-03-03
- Enrolment
- 32
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAcute Lymphoblastic Leukemia; Diffuse Large B Cell Lymphoma; Primary Mediastinal LymphomaInterventionCD19-CAR_Lenti T cellPhasePhase 1 / Phase 2Registry statusActive not recruitingNatural Killer-cell Therapy for Acute Myeloid Leukemia
NCT04347616 · start 2020-12-03
Registered record
- Registry ID
- NCT04347616
- Conditions
- Acute Myeloid Leukemia Refractory; Acute Myeloid Leukemia, Relapsed, Adult
- Interventions
- UCB-NK cells; IL-2
- Study type
- INTERVENTIONAL
- Phase
- Phase 1 / Phase 2
- Registry status
- Terminated
- Start
- 2020-12-03
- Completion
- 2026-01-30
- Enrolment
- 9
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAcute Myeloid Leukemia Refractory; Acute Myeloid Leukemia, Relapsed, AdultInterventionUCB-NK cells; IL-2PhasePhase 1 / Phase 2Registry statusTerminatedGD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas (DIPG) & Spinal Diffuse Midline Glioma(DMG)
NCT04196413 · start 2020-06-04
Registered record
- Registry ID
- NCT04196413
- Conditions
- Glioma of Spinal Cord; Glioma of Brainstem
- Interventions
- GD2 CAR T cells; Fludarabine; Cyclophosphamide; Rituximab
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Recruiting
- Start
- 2020-06-04
- Completion
- 2043-07-31
- Enrolment
- 97
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionGlioma of Spinal Cord; Glioma of BrainstemInterventionGD2 CAR T cells; Fludarabine; Cyclophosphamide; RituximabPhasePhase 1Registry statusRecruitingA Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering
NCT04426669 · start 2020-05-15
Registered record
- Registry ID
- NCT04426669
- Conditions
- Gastrointestinal Epithelial Cancer; Gastrointestinal Neoplasms; Cancer of Gastrointestinal Tract; Cancer, Gastrointestinal; Gastrointestinal Cancer; Colo-rectal Cancer; Pancreatic Cancer; Gall Bladder Cancer; Colon Cancer; Esophageal Cancer; Stomach Cancer
- Interventions
- Cyclophosphamide; Fludarabine; Tumor-Infiltrating Lymphocytes (TIL); Aldesleukin
- Study type
- INTERVENTIONAL
- Phase
- Phase 1 / Phase 2
- Registry status
- Completed
- Start
- 2020-05-15
- Completion
- 2026-01-22
- Enrolment
- 23
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionGastrointestinal Epithelial Cancer; Gastrointestinal Neoplasms; Cancer of Gastrointestinal Tract; Cancer, Gastrointestinal +7 moreInterventionCyclophosphamide; Fludarabine; Tumor-Infiltrating Lymphocytes (TIL); AldesleukinPhasePhase 1 / Phase 2Registry statusCompletedStem Cell Transplantation in Crohn's Disease
NCT04224558 · start 2019-11-15
Registered record
- Registry ID
- NCT04224558
- Conditions
- Crohn Disease
- Interventions
- Mesna; Cyclophosphamide; Filgrastim; Apheresis catheter placement; Leukapheresis; Fludarabine; Methylprednisolone; Diphenhydramine; Acetaminophen; anti-thymocyte globulin (rabbit); lymphocyte immune globulin; Peripheral Blood Stem Cell Infusion; Cytoxan
- Study type
- INTERVENTIONAL
- Phase
- Phase 1 / Phase 2
- Registry status
- Recruiting
- Start
- 2019-11-15
- Completion
- 2027-09-30
- Enrolment
- 15
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCrohn DiseaseInterventionMesna; Cyclophosphamide; Filgrastim; Apheresis catheter placement +9 morePhasePhase 1 / Phase 2Registry statusRecruitingCytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant
NCT03622788 · start 2019-08-08
Registered record
- Registry ID
- NCT03622788
- Conditions
- Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Aplastic Anemia; Bone Marrow Failure; Chronic Lymphocytic Leukemia; Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Follicular Lymphoma; Hodgkin Lymphoma; Mantle Cell Lymphoma; Myelodysplastic Syndrome; Myeloproliferative Neoplasm; Non-Hodgkin Lymphoma; Plasma Cell Myeloma
- Interventions
- Anti-Thymocyte Globulin; Cyclophosphamide; Cytokine-treated Veto Cells; Fludarabine; Peripheral Blood Stem Cell Transplantation; Total-Body Irradiation
- Study type
- INTERVENTIONAL
- Phase
- Phase 1 / Phase 2
- Registry status
- Active not recruiting
- Start
- 2019-08-08
- Completion
- 2027-12-01
- Enrolment
- 16
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAcute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Aplastic Anemia; Bone Marrow Failure +9 moreInterventionAnti-Thymocyte Globulin; Cyclophosphamide; Cytokine-treated Veto Cells; Fludarabine +2 morePhasePhase 1 / Phase 2Registry statusActive not recruitingUM171 Expanded Cord Blood In Patients With High-Risk Acute Leukemia/Myelodysplasia
NCT03913026 · start 2019-04-01
Registered record
- Registry ID
- NCT03913026
- Conditions
- High Risk Hematologic Malignancy; Cord Blood Transplant
- Interventions
- Transplant with an expanded ECT-001 cord blood
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Active not recruiting
- Start
- 2019-04-01
- Completion
- 2027-06
- Enrolment
- 30
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHigh Risk Hematologic Malignancy; Cord Blood TransplantInterventionTransplant with an expanded ECT-001 cord bloodPhasePhase 2Registry statusActive not recruitingAllogeneic Immunotherapy for Hematological Malignancies by Selective Depletion of Regulatory T Cells
NCT03236129 · start 2018-02-22
Registered record
- Registry ID
- NCT03236129
- Conditions
- Hematological Malignancies; Regulatory T Cell Depletion; Relapse
- Interventions
- T-reg depleted DLI; Standard DLI
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Unknown
- Start
- 2018-02-22
- Completion
- 2026-02
- Enrolment
- 52
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHematological Malignancies; Regulatory T Cell Depletion; RelapseInterventionT-reg depleted DLI; Standard DLIPhasePhase 3Registry statusUnknownHaploidentical Bone Marrow Transplantation in Sickle Cell Patients (BMTCTN1507)
NCT03263559 · start 2017-10-03
Registered record
- Registry ID
- NCT03263559
- Conditions
- Sickle Cell Disease
- Interventions
- Haploidentical Bone Marrow Transplantation; Hydroxyurea; Rabbit-ATG; Thiotepa; Fludarabine; Cyclophosphamide; Total Body Irradiation; Mesna
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2017-10-03
- Completion
- 2025-01-29
- Enrolment
- 95
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSickle Cell DiseaseInterventionHaploidentical Bone Marrow Transplantation; Hydroxyurea; Rabbit-ATG; Thiotepa +4 morePhasePhase 2Registry statusCompleted